{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:47:29Z","timestamp":1793760449320,"version":"4.6.1"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The work was funded by the Sutardja Chuk Professorship for Definitive and Curative Medicine and the Laurie Kraus Lacob Fund for Pediatric Translational Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-58371-8","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T21:13:55Z","timestamp":1743455635000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Multilayered HIV-1 resistance in HSPCs through CCR5 Knockout and B cell secretion of HIV-inhibiting antibodies"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5870-4460","authenticated-orcid":false,"given":"William N.","family":"Feist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9173-9518","authenticated-orcid":false,"given":"Sofia E.","family":"Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaya","family":"Ben-Efraim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria V.","family":"Filsinger Interrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3500-5085","authenticated-orcid":false,"given":"Alvaro","family":"Amorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora U. J.","family":"Bruun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2280-8521","authenticated-orcid":false,"given":"Ashley","family":"Utz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana Y.","family":"Ghanim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Lesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa M.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0239-3576","authenticated-orcid":false,"given":"Amanda M.","family":"Dudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3850-4648","authenticated-orcid":false,"given":"Matthew H.","family":"Porteus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"58371_CR1","unstructured":"Joint United Nations Programme on HIV\/AIDS. The path that ends AIDS: UNAIDS Global AIDS Update 2023. UNAIDS repor (Joint United Nations Programme on HIV\/AIDS, 2023)."},{"key":"58371_CR2","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/hiv.12421","volume":"18","author":"S Teeraananchai","year":"2017","unstructured":"Teeraananchai, S., Kerr, S., Amin, J., Ruxrungtham, K. & Law, M. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 18, 256\u2013266 (2017).","journal-title":"HIV Med."},{"key":"58371_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2022.22246","volume":"329","author":"RT Gandhi","year":"2023","unstructured":"Gandhi, R. T. et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults. JAMA 329, 63 (2023).","journal-title":"JAMA"},{"key":"58371_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.7326\/0003-4819-133-1-200007040-00004","volume":"133","author":"DL Paterson","year":"2000","unstructured":"Paterson, D. L. et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133, 21\u201330 (2000).","journal-title":"Ann. Intern. Med."},{"key":"58371_CR5","doi-asserted-by":"publisher","first-page":"S143","DOI":"10.1086\/340197","volume":"185","author":"T Barbara","year":"2002","unstructured":"Barbara, T. Adherence to antiretroviral therapy by human immunodeficiency virus\u2013infected patients. J. Infect. Dis. 185, S143\u2013S151 (2002).","journal-title":"J. Infect. Dis."},{"key":"58371_CR6","doi-asserted-by":"publisher","unstructured":"Kim, J., Lee, E., Park, B.-J., Bang, J. H. & Lee, J. Y. Adherence to antiretroviral therapy and factors affecting low medication adherence among incident HIV-infected individuals during 2009\u20132016: a nationwide study. Sci. Rep. 8, https:\/\/doi.org\/10.1038\/s41598-018-21081-x (2018).","DOI":"10.1038\/s41598-018-21081-x"},{"key":"58371_CR7","doi-asserted-by":"publisher","first-page":"13193","DOI":"10.1073\/pnas.94.24.13193","volume":"94","author":"TW Chun","year":"1997","unstructured":"Chun, T. W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94, 13193\u201313197 (1997).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"58371_CR8","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","volume":"278","author":"D Finzi","year":"1997","unstructured":"Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295 (1997).","journal-title":"Science"},{"key":"58371_CR9","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/infdis\/jiaa377","volume":"223","author":"S Mahomed","year":"2021","unstructured":"Mahomed, S., Garrett, N., Baxter, C., Abdool Karim, Q. & Abdool Karim, S. S. Clinical trials of broadly neutralizing monoclonal antibodies for human immunodeficiency virus prevention: a review. J. Infect. Dis. 223, 370\u2013380 (2021).","journal-title":"J. Infect. Dis."},{"key":"58371_CR10","doi-asserted-by":"crossref","unstructured":"Frattari, G. S., Caskey, M. & S\u00f8gaard, O. S. Broadly neutralizing antibodies for HIV treatment and cure approaches. Curr. Opin. HIV AIDS 18, 157\u2013163 (2023).","DOI":"10.1097\/COH.0000000000000802"},{"key":"58371_CR11","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40265-018-0907-5","volume":"78","author":"A Markham","year":"2018","unstructured":"Markham, A. Ibalizumab: first global approval. Drugs 78, 781\u2013785 (2018).","journal-title":"Drugs"},{"key":"58371_CR12","doi-asserted-by":"crossref","unstructured":"Pace, C. S. et al. Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 Glycan in Envelope. JAIDS J. Acquir. Immune Deficiency Syndromes 62, 1\u20139 (2013).","DOI":"10.1097\/QAI.0b013e3182732746"},{"key":"58371_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0300-483X(02)00002-1","volume":"172","author":"L Boon","year":"2002","unstructured":"Boon, L. Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates. Toxicology 172, 191\u2013203 (2002).","journal-title":"Toxicology"},{"key":"58371_CR14","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa1711460","volume":"379","author":"B Emu","year":"2018","unstructured":"Emu, B. et al. Phase 3 study of Ibalizumab for Multidrug-Resistant HIV-1. N. Engl. J. Med. 379, 645\u2013654 (2018).","journal-title":"N. Engl. J. Med."},{"key":"58371_CR15","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s41590-018-0235-7","volume":"19","author":"D Sok","year":"2018","unstructured":"Sok, D. & Burton, D. R. Recent progress in broadly neutralizing antibodies to HIV. Nat. Immunol. 19, 1179\u20131188 (2018).","journal-title":"Nat. Immunol."},{"key":"58371_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/COH.0000000000000600","volume":"15","author":"M Caskey","year":"2020","unstructured":"Caskey, M. Broadly neutralizing antibodies for the treatment and prevention of HIV infection. Curr. Opin. HIV AIDS 15, 49\u201355 (2020).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"58371_CR17","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","volume":"561","author":"P Mendoza","year":"2018","unstructured":"Mendoza, P. et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature 561, 479\u2013484 (2018).","journal-title":"Nature"},{"key":"58371_CR18","doi-asserted-by":"publisher","unstructured":"Gaebler, C. et al. Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature, https:\/\/doi.org\/10.1038\/s41586-022-04597-1 (2022).","DOI":"10.1038\/s41586-022-04597-1"},{"key":"58371_CR19","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/s41591-022-01815-1","volume":"28","author":"B Julg","year":"2022","unstructured":"Julg, B. et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nat. Med. 28, 1288\u20131296 (2022).","journal-title":"Nat. Med."},{"key":"58371_CR20","doi-asserted-by":"publisher","unstructured":"Badamchi-Zadeh, A. et al. Therapeutic efficacy of Vectored PGT121 gene delivery in HIV-1-Infected humanized mice. J. Virol. 92, https:\/\/doi.org\/10.1128\/JVI.01925-17 (2018).","DOI":"10.1128\/JVI.01925-17"},{"key":"58371_CR21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.omtm.2019.06.002","volume":"14","author":"FT van den Berg","year":"2019","unstructured":"van den Berg, F. T. et al. AAV-Mediated expression of broadly neutralizing and vaccine-like antibodies targeting the HIV-1 envelope V2 Region. Mol. Ther. Methods Clin. Dev. 14, 100\u2013112 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"58371_CR22","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.immuni.2019.02.005","volume":"50","author":"JM Martinez-Navio","year":"2019","unstructured":"Martinez-Navio, J. M. et al. Adeno-associated virus delivery of Anti-HIV monoclonal antibodies can drive long-term virologic suppression. Immunity 50, 567\u2013575.e565 (2019).","journal-title":"Immunity"},{"key":"58371_CR23","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3389\/fimmu.2020.00449","volume":"11","author":"JM Martinez-Navio","year":"2020","unstructured":"Martinez-Navio, J. M. et al. Long-term delivery of an Anti-SIV monoclonal antibody with AAV. Front. Immunol. 11, 449 (2020).","journal-title":"Front. Immunol."},{"key":"58371_CR24","unstructured":"Casazza, J. P. et al. Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Nat. Med. 28, 1022\u20131030 (2022)."},{"key":"58371_CR25","first-page":"191","volume":"18","author":"LR Joshi","year":"2023","unstructured":"Joshi, L. R., G\u00e1lvez, N. M. S., Ghosh, S., Weiner, D. B. & Balazs, A. B. Delivery platforms for broadly neutralizing antibodies. Curr. Opin. HIV AIDS 18, 191\u2013208 (2023).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"58371_CR26","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1089\/hum.2021.287","volume":"33","author":"R Klamroth","year":"2022","unstructured":"Klamroth, R. et al. Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A. Hum. Gene Ther. 33, 432\u2013441 (2022).","journal-title":"Hum. Gene Ther."},{"key":"58371_CR27","doi-asserted-by":"publisher","first-page":"e230","DOI":"10.1016\/S2352-3018(19)30003-7","volume":"6","author":"FH Priddy","year":"2019","unstructured":"Priddy, F. H. et al. Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. Lancet HIV 6, e230\u2013e239 (2019).","journal-title":"Lancet HIV"},{"key":"58371_CR28","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ymthe.2017.11.012","volume":"26","author":"KL Hung","year":"2018","unstructured":"Hung, K. L. et al. Engineering protein-secreting plasma cells by homology-directed repair in primary human B cells. Mol. Ther. 26, 456\u2013467 (2018).","journal-title":"Mol. Ther."},{"key":"58371_CR29","doi-asserted-by":"publisher","first-page":"eaax0644","DOI":"10.1126\/sciimmunol.aax0644","volume":"4","author":"HF Moffett","year":"2019","unstructured":"Moffett, H. F. et al. B cells engineered to express pathogen-specific antibodies protect against infection. Sci. Immunol. 4, eaax0644 (2019).","journal-title":"Sci. Immunol."},{"key":"58371_CR30","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1084\/jem.20190287","volume":"216","author":"H Hartweger","year":"2019","unstructured":"Hartweger, H. et al. HIV-specific humoral immune responses by CRISPR\/Cas9-edited B cells. J. Exp. Med. 216, 1301\u20131310 (2019).","journal-title":"J. Exp. Med."},{"key":"58371_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19649-1","volume":"11","author":"AD Nahmad","year":"2020","unstructured":"Nahmad, A. D. et al. Engineered B cells expressing an anti-HIV antibody enable memory retention, isotype switching and clonal expansion. Nat. Commun. 11, 5851 (2020).","journal-title":"Nat. Commun."},{"key":"58371_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19650-8","volume":"11","author":"D Huang","year":"2020","unstructured":"Huang, D. et al. Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells. Nat. Commun. 11, 5850 (2020).","journal-title":"Nat. Commun."},{"key":"58371_CR33","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa0802905","volume":"360","author":"G H\u00fctter","year":"2009","unstructured":"H\u00fctter, G. et al. Long-Term control of HIV byCCR5Delta32\/Delta32 stem-cell transplantation. N. Engl. J. Med. 360, 692\u2013698 (2009).","journal-title":"N. Engl. J. Med."},{"key":"58371_CR34","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","volume":"568","author":"RK Gupta","year":"2019","unstructured":"Gupta, R. K. et al. HIV-1 remission following CCR5\u039432\/\u039432 haematopoietic stem-cell transplantation. Nature 568, 244\u2013248 (2019).","journal-title":"Nature"},{"key":"58371_CR35","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41591-023-02213-x","volume":"29","author":"B-EO Jensen","year":"2023","unstructured":"Jensen, B.-E. O. et al. In-depth virological and immunological characterization of HIV-1 cure after CCR5\u039432\/\u039432 allogeneic hematopoietic stem cell transplantation. Nat. Med. 29, 583\u2013587 (2023).","journal-title":"Nat. Med."},{"key":"58371_CR36","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.humimm.2017.10.001","volume":"78","author":"UV Solloch","year":"2017","unstructured":"Solloch, U. V. et al. Frequencies of gene variant CCR5-\u039432 in 87 countries based on next-generation sequencing of 1.3 million individuals sampled from 3 national DKMS donor centers. Hum. Immunol. 78, 710\u2013717 (2017).","journal-title":"Hum. Immunol."},{"key":"58371_CR37","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1056\/NEJMsa1311707","volume":"371","author":"L Gragert","year":"2014","unstructured":"Gragert, L. et al. HLA Match likelihoods for hematopoietic stem-cell grafts in the U.S. Registry. N. Engl. J. Med. 371, 339\u2013348 (2014).","journal-title":"N. Engl. J. Med."},{"key":"58371_CR38","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41409-019-0624-z","volume":"55","author":"J Styczy\u0144ski","year":"2020","unstructured":"Styczy\u0144ski, J. et al. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transplant. 55, 126\u2013136 (2020).","journal-title":"Bone Marrow Transplant."},{"key":"58371_CR39","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1056\/NEJMc1405805","volume":"371","author":"L Kordelas","year":"2014","unstructured":"Kordelas, L., Verheyen, J. & Esser, S. Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N. Engl. J. Med. 371, 880\u2013882 (2014).","journal-title":"N. Engl. J. Med."},{"key":"58371_CR40","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1086\/431519","volume":"192","author":"ZL Brumme","year":"2005","unstructured":"Brumme, Z. L. et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J. Infect. Dis. 192, 466\u2013474 (2005).","journal-title":"J. Infect. Dis."},{"key":"58371_CR41","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1086\/591623","volume":"198","author":"J Shepherd","year":"2008","unstructured":"Shepherd, J. et al. Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study. J. Infect. Dis. 198, 1104\u20131112 (2008).","journal-title":"J. Infect. Dis."},{"key":"58371_CR42","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1056\/NEJMoa1817426","volume":"381","author":"L Xu","year":"2019","unstructured":"Xu, L. et al. CRISPR-Edited stem cells in a patient with HIV and acute lymphocytic leukemia. N. Engl. J. Med. 381, 1240\u20131247 (2019).","journal-title":"N. Engl. J. Med."},{"key":"58371_CR43","doi-asserted-by":"publisher","first-page":"16067","DOI":"10.1038\/mtm.2016.67","volume":"3","author":"DL DiGiusto","year":"2016","unstructured":"DiGiusto, D. L. et al. Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem\/progenitor cells. Mol. Ther. Methods Clin. Dev. 3, 16067\u201316067 (2016).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"58371_CR44","doi-asserted-by":"publisher","first-page":"e236","DOI":"10.1038\/mtna.2015.10","volume":"4","author":"BP Burke","year":"2015","unstructured":"Burke, B. P. et al. Engineering cellular resistance to HIV-1 infection in vivo using a dual therapeutic lentiviral vector. Mol. Ther. Nucleic Acids 4, e236 (2015).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"58371_CR45","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1182\/blood-2008-09-177139","volume":"113","author":"XM Luo","year":"2009","unstructured":"Luo, X. M. et al. Engineering human hematopoietic stem\/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes. Blood 113, 1422\u20131431 (2009).","journal-title":"Blood"},{"key":"58371_CR46","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ymthe.2018.09.017","volume":"27","author":"A-S Kuhlmann","year":"2019","unstructured":"Kuhlmann, A.-S. et al. Long-term persistence of Anti-HIV broadly neutralizing antibody-secreting hematopoietic cells in humanized mice. Mol. Ther. 27, 164\u2013177 (2019).","journal-title":"Mol. Ther."},{"key":"58371_CR47","doi-asserted-by":"crossref","unstructured":"Wolstein, O. et al. Preclinical safety and efficacy of an anti\u2013HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor. Mol. Ther. Methods Clini. Dev. 1, e11 (2014).","DOI":"10.1038\/mtm.2013.11"},{"key":"58371_CR48","doi-asserted-by":"publisher","first-page":"e53492","DOI":"10.1371\/journal.pone.0053492","volume":"7","author":"G-EE Ringpis","year":"2012","unstructured":"Ringpis, G.-E. E. et al. Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem\/progenitor cells in humanized BLT mice. PloS ONE 7, e53492 (2012).","journal-title":"PloS ONE"},{"key":"58371_CR49","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.ymthe.2005.07.358","volume":"12","author":"M Themis","year":"2005","unstructured":"Themis, M. et al. Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol. Ther. 12, 763\u2013771 (2005).","journal-title":"Mol. Ther."},{"key":"58371_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/hum.2023.29263.bfs","volume":"35","author":"A Philippidis","year":"2024","unstructured":"Philippidis, A. CASGEVY makes history as FDA Approves First CRISPR\/Cas9 genome edited therapy. Human Gene Ther. 35, 1\u20134 (2024).","journal-title":"Human Gene Ther."},{"key":"58371_CR51","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.stem.2024.03.002","volume":"31","author":"AM Dudek","year":"2024","unstructured":"Dudek, A. M. et al. A simultaneous knockout knockin genome editing strategy in HSPCs potently inhibits CCR5- and CXCR4-tropic HIV-1 infection. Cell Stem Cell 31, 499\u2013518.e496 (2024).","journal-title":"Cell Stem Cell"},{"key":"58371_CR52","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nm.4268","volume":"23","author":"M Caskey","year":"2017","unstructured":"Caskey, M. et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat. Med. 23, 185\u2013191 (2017).","journal-title":"Nat. Med."},{"key":"58371_CR53","doi-asserted-by":"publisher","first-page":"17624","DOI":"10.1073\/pnas.1415789111","volume":"111","author":"D Sok","year":"2014","unstructured":"Sok, D. et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc. Natl. Acad. Sci. USA 111, 17624\u201317629 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"58371_CR54","doi-asserted-by":"publisher","unstructured":"Zhang, B. et al. Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life. Sci. Rep. 12, https:\/\/doi.org\/10.1038\/s41598-022-22435-2 (2022).","DOI":"10.1038\/s41598-022-22435-2"},{"key":"58371_CR55","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nature14411","volume":"522","author":"M Caskey","year":"2015","unstructured":"Caskey, M. et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487\u2013491 (2015).","journal-title":"Nature"},{"key":"58371_CR56","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.cell.2020.01.010","volume":"180","author":"P Schommers","year":"2020","unstructured":"Schommers, P. et al. Restriction of HIV-1 escape by a highly broad and potent neutralizing antibody. Cell 180, 471\u2013489.e422 (2020).","journal-title":"Cell"},{"key":"58371_CR57","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jmb.2014.11.017","volume":"427","author":"JT Koerber","year":"2015","unstructured":"Koerber, J. T., Hornsby, M. J. & Wells, J. A. An improved single-chain Fab platform for efficient display and recombinant expression. J. Mol. Biol. 427, 576\u2013586 (2015).","journal-title":"J. Mol. Biol."},{"key":"58371_CR58","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1128\/JVI.02853-13","volume":"88","author":"A deCamp","year":"2014","unstructured":"deCamp, A. et al. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 88, 2489\u20132507 (2014).","journal-title":"J. Virol."},{"key":"58371_CR59","doi-asserted-by":"publisher","first-page":"W213","DOI":"10.1093\/nar\/gkv404","volume":"43","author":"H Yoon","year":"2015","unstructured":"Yoon, H. et al. CATNAP: a tool to compile, analyze and tally neutralizing antibody panels. Nucleic Acids Res. 43, W213\u2013W219 (2015).","journal-title":"Nucleic Acids Res."},{"key":"58371_CR60","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/s41591-018-0137-0","volume":"24","author":"CA Vakulskas","year":"2018","unstructured":"Vakulskas, C. A. et al. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat. Med. 24, 1216\u20131224 (2018).","journal-title":"Nat. Med."},{"key":"58371_CR61","doi-asserted-by":"publisher","unstructured":"Selvaraj, S. et al. High-efficiency transgene integration by homology-directed repair in human primary cells using DNA-PKcs inhibition. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-023-01888-4 (2023).","DOI":"10.1038\/s41587-023-01888-4"},{"key":"58371_CR62","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature20134","volume":"539","author":"DP Dever","year":"2016","unstructured":"Dever, D. P. et al. CRISPR\/Cas9 \u03b2-globin gene targeting in human haematopoietic stem cells. Nature 539, 384\u2013389 (2016).","journal-title":"Nature"},{"key":"58371_CR63","doi-asserted-by":"publisher","unstructured":"Gomez-Ospina, N. et al. Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I. Nat. Commun. 10, https:\/\/doi.org\/10.1038\/s41467-019-11962-8 (2019).","DOI":"10.1038\/s41467-019-11962-8"},{"key":"58371_CR64","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/s41591-021-01284-y","volume":"27","author":"MK Cromer","year":"2021","unstructured":"Cromer, M. K. et al. Gene replacement of \u03b1-globin with \u03b2-globin restores hemoglobin balance in \u03b2-thalassemia-derived hematopoietic stem and progenitor cells. Nat. Med. 27, 677\u2013687 (2021).","journal-title":"Nat. Med."},{"key":"58371_CR65","doi-asserted-by":"crossref","unstructured":"Vavassori, V. et al. Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells. Blood 142, 812\u2013826 (2023).","DOI":"10.1182\/blood.2022019333"},{"key":"58371_CR66","doi-asserted-by":"publisher","first-page":"360ra134","DOI":"10.1126\/scitranslmed.aaf9336","volume":"8","author":"MA DeWitt","year":"2016","unstructured":"DeWitt, M. A. et al. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem\/progenitor cells. Sci. Transl. Med. 8, 360ra134 (2016).","journal-title":"Sci. Transl. Med."},{"key":"58371_CR67","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature13420","volume":"510","author":"P Genovese","year":"2014","unstructured":"Genovese, P. et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature 510, 235\u2013240 (2014).","journal-title":"Nature"},{"key":"58371_CR68","doi-asserted-by":"publisher","unstructured":"Lattanzi, A. et al. Development of \u03b2-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. Sci. Transl. Med. 13, https:\/\/doi.org\/10.1126\/scitranslmed.abf2444 (2021).","DOI":"10.1126\/scitranslmed.abf2444"},{"key":"58371_CR69","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.omtm.2023.07.009","volume":"30","author":"L Xu","year":"2023","unstructured":"Xu, L. et al. Molecular dynamics of genome editing with CRISPR-Cas9 and rAAV6 virus in human HSPCs to treat sickle cell disease. Mol. Ther. Methods Clin. Dev. 30, 317\u2013331 (2023).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"58371_CR70","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s12026-011-8243-9","volume":"51","author":"R Vuyyuru","year":"2011","unstructured":"Vuyyuru, R., Patton, J. & Manser, T. Human immune system mice: current potential and limitations for translational research on human antibody responses. Immunol. Res. 51, 257\u2013266 (2011).","journal-title":"Immunol. Res."},{"key":"58371_CR71","doi-asserted-by":"crossref","unstructured":"Jangalwe, S., Shultz, L. D., Mathew, A. & Brehm, M. A. Improved B cell development in humanized NOD-scid IL2R\u03b3(null) mice transgenically expressing human stem cell factor, granulocyte-macrophage colony-stimulating factor and interleukin-3. Immunity Inflamm. Dis. 4, 427\u2013440 (2016).","DOI":"10.1002\/iid3.124"},{"key":"58371_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-017-0209-9","volume":"18","author":"A Audig\u00e9","year":"2017","unstructured":"Audig\u00e9, A. et al. Long-term leukocyte reconstitution in NSG mice transplanted with human cord blood hematopoietic stem and progenitor cells. BMC Immunol. 18, 28 (2017).","journal-title":"BMC Immunol."},{"key":"58371_CR73","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10875-010-9478-2","volume":"31","author":"B Choi","year":"2011","unstructured":"Choi, B. et al. Human B cell development and antibody production in humanized NOD\/SCID\/IL-2R\u03b3null (NSG) mice conditioned by Busulfan. J. Clin. Immunol. 31, 253\u2013264 (2011).","journal-title":"J. Clin. Immunol."},{"key":"58371_CR74","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/cei\/uxac104","volume":"210","author":"RL Velounias","year":"2022","unstructured":"Velounias, R. L. & Tull, T. J. Human B-cell subset identification and changes in inflammatory diseases. Clin. Exp. Immunol. 210, 201\u2013216 (2022).","journal-title":"Clin. Exp. Immunol."},{"key":"58371_CR75","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41590-021-01088-9","volume":"23","author":"RC Brewer","year":"2022","unstructured":"Brewer, R. C. et al. BNT162b2 vaccine induces divergent B cell responses to SARS-CoV-2 S1 and S2. Nat. Immunol. 23, 33\u201339 (2022).","journal-title":"Nat. Immunol."},{"key":"58371_CR76","doi-asserted-by":"crossref","unstructured":"Leonard, A. & Tisdale, J. F. A new frontier: FDA approvals for gene therapy in sickle cell disease. Mol. Ther. 32, 264\u2013267 (2024).","DOI":"10.1016\/j.ymthe.2024.01.015"},{"key":"58371_CR77","doi-asserted-by":"publisher","first-page":"660302","DOI":"10.3389\/fimmu.2021.660302","volume":"12","author":"AM Dudek","year":"2021","unstructured":"Dudek, A. M. & Porteus, M. H. Answered and unanswered questions in early-stage viral vector transduction biology and innate primary cell toxicity for ex-vivo gene editing. Front. Immunol. 12, 660302 (2021).","journal-title":"Front. Immunol."},{"key":"58371_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43413-w","volume":"15","author":"R Baik","year":"2024","unstructured":"Baik, R. et al. Transient inhibition of 53BP1 increases the frequency of targeted integration in human hematopoietic stem and progenitor cells. Nat. Commun. 15, 111 (2024).","journal-title":"Nat. Commun."},{"key":"58371_CR79","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.stem.2019.02.019","volume":"24","author":"G Schiroli","year":"2019","unstructured":"Schiroli, G. et al. Precise gene editing preserves hematopoietic stem cell function following transient p53-Mediated DNA damage response. Cell Stem Cell 24, 551\u2013565.e558 (2019).","journal-title":"Cell Stem Cell"},{"key":"58371_CR80","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.idc.2019.02.007","volume":"33","author":"M Kamboj","year":"2019","unstructured":"Kamboj, M. & Shah, M. K. Vaccination of the stem cell transplant recipient and the hematologic malignancy patient. Infect. Dis. Clin. North Am. 33, 593\u2013609 (2019).","journal-title":"Infect. Dis. Clin. North Am."},{"key":"58371_CR81","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1080\/07388551.2017.1416577","volume":"38","author":"JB Goh","year":"2018","unstructured":"Goh, J. B. & Ng, S. K. Impact of host cell line choice on glycan profile. Crit. Rev. Biotechnol. 38, 851\u2013867 (2018).","journal-title":"Crit. Rev. Biotechnol."},{"key":"58371_CR82","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ymthe.2019.01.004","volume":"27","author":"MR Gardner","year":"2019","unstructured":"Gardner, M. R. et al. Anti-drug antibody responses impair prophylaxis mediated by AAV-Delivered HIV-1 broadly neutralizing antibodies. Mol. Ther. 27, 650\u2013660 (2019).","journal-title":"Mol. Ther."},{"key":"58371_CR83","doi-asserted-by":"publisher","first-page":"112736","DOI":"10.1016\/j.jim.2020.112736","volume":"479","author":"MS Seaman","year":"2020","unstructured":"Seaman, M. S. et al. Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbs. J. Immunol. Methods 479, 112736 (2020).","journal-title":"J. Immunol. Methods"},{"key":"58371_CR84","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/ph3010146","volume":"3","author":"R Ab\u00e8s","year":"2010","unstructured":"Ab\u00e8s, R. & Teillaud, J.-L. Impact of Glycosylation on effector functions of therapeutic IgG. Pharmaceuticals 3, 146\u2013157 (2010).","journal-title":"Pharmaceuticals"},{"key":"58371_CR85","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1002\/jps.24444","volume":"104","author":"L Liu","year":"2015","unstructured":"Liu, L. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-Fusion proteins. J. Pharm. Sci. 104, 1866\u20131884 (2015).","journal-title":"J. Pharm. Sci."},{"key":"58371_CR86","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.3389\/fimmu.2020.02044","volume":"11","author":"M Trist\u00e1n-Manzano","year":"2020","unstructured":"Trist\u00e1n-Manzano, M. et al. Externally-controlled systems for immunotherapy: from bench to bedside. Front. Immunol. 11, 2044 (2020).","journal-title":"Front. Immunol."},{"key":"58371_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19532-z","volume":"11","author":"A Yesbolatova","year":"2020","unstructured":"Yesbolatova, A. et al. The auxin-inducible degron 2 technology provides sharp degradation control in yeast, mammalian cells, and mice. Nat. Commun. 11, 5701 (2020).","journal-title":"Nat. Commun."},{"key":"58371_CR88","doi-asserted-by":"publisher","first-page":"e77987","DOI":"10.7554\/eLife.77987","volume":"11","author":"L Macdonald","year":"2022","unstructured":"Macdonald, L. et al. Rapid and specific degradation of endogenous proteins in mouse models using auxin-inducible degrons. eLife 11, e77987 (2022).","journal-title":"eLife"},{"key":"58371_CR89","doi-asserted-by":"publisher","first-page":"eadk4422","DOI":"10.1126\/science.adk4422","volume":"383","author":"JA Mercer","year":"2024","unstructured":"Mercer, J. A. et al. Continuous evolution of compact protein degradation tags regulated by selective molecular glues. Science 383, eadk4422 (2024).","journal-title":"Science"},{"key":"58371_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16455-7","volume":"11","author":"RM Martin","year":"2020","unstructured":"Martin, R. M. et al. Improving the safety of human pluripotent stem cell therapies using genome-edited orthogonal safeguards. Nat. Commun. 11, 2713 (2020).","journal-title":"Nat. Commun."},{"key":"58371_CR91","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.coi.2021.07.002","volume":"74","author":"AC Sahillioglu","year":"2022","unstructured":"Sahillioglu, A. C. & Schumacher, T. N. Safety switches for adoptive cell therapy. Curr. Opin. Immunol. 74, 190\u2013198 (2022).","journal-title":"Curr. Opin. Immunol."},{"key":"58371_CR92","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1089\/hgtb.2011.034","volume":"23","author":"C Aurnhammer","year":"2012","unstructured":"Aurnhammer, C. et al. Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. Hum. Gene Ther. Methods 23, 18\u201328 (2012).","journal-title":"Hum. Gene Ther. Methods"},{"key":"58371_CR93","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nprot.2017.143","volume":"13","author":"RO Bak","year":"2018","unstructured":"Bak, R. O., Dever, D. P. & Porteus, M. H. CRISPR\/Cas9 genome editing in human hematopoietic stem cells. Nat. Protoc. 13, 358\u2013376 (2018).","journal-title":"Nat. Protoc."},{"key":"58371_CR94","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nbt.3290","volume":"33","author":"A Hendel","year":"2015","unstructured":"Hendel, A. et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat. Biotechnol. 33, 985\u2013989 (2015).","journal-title":"Nat. Biotechnol."},{"key":"58371_CR95","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.omtm.2021.09.003","volume":"23","author":"GL Rogers","year":"2021","unstructured":"Rogers, G. L. et al. Optimization of AAV6 transduction enhances site-specific genome editing of primary human lymphocytes. Mol. Ther. Methods Clin. Dev. 23, 198\u2013209 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"58371_CR96","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1089\/crispr.2021.0113","volume":"5","author":"D Conant","year":"2022","unstructured":"Conant, D. et al. Inference of CRISPR Edits from Sanger Trace Data. Crispr J. 5, 123\u2013130 (2022).","journal-title":"Crispr J."},{"key":"58371_CR97","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.1038\/mtna.2014.64","volume":"3","author":"TJ Cradick","year":"2014","unstructured":"Cradick, T. J., Qiu, P., Lee, C. M., Fine, E. J. & Bao, G. COSMID: a web-based tool for identifying and validating CRISPR\/Cas Off-target Sites. Mol. Ther. Nucleic Acids 3, e214 (2014).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"58371_CR98","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41587-019-0032-3","volume":"37","author":"K Clement","year":"2019","unstructured":"Clement, K. et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat. Biotechnol. 37, 224\u2013226 (2019).","journal-title":"Nat. Biotechnol."},{"key":"58371_CR99","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn9662","volume":"14","author":"JM Brady","year":"2022","unstructured":"Brady, J. M. et al. Antibody-mediated prevention of vaginal HIV transmission is dictated by IgG subclass in humanized mice. Sci. Transl. Med. 14, eabn9662 (2022).","journal-title":"Sci. Transl. Med."},{"key":"58371_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-15506-x","volume":"12","author":"K-MA Dam","year":"2022","unstructured":"Dam, K.-M. A., Mutia, P. S. & Bjorkman, P. J. Comparing methods for immobilizing HIV-1 SOSIPs in ELISAs that evaluate antibody binding. Sci. Rep. 12, 11172 (2022).","journal-title":"Sci. Rep."},{"key":"58371_CR101","doi-asserted-by":"crossref","unstructured":"Montefiori, D. C. Measuring HIV neutralization in a luciferase reporter gene assay. HIV Protoc. 485, 395\u2013405 (2009).","DOI":"10.1007\/978-1-59745-170-3_26"},{"key":"58371_CR102","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","volume":"409","author":"M Sarzotti-Kelsoe","year":"2014","unstructured":"Sarzotti-Kelsoe, M. et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J. Immunol. Methods 409, 131\u2013146 (2014).","journal-title":"J. Immunol. Methods"},{"key":"58371_CR103","doi-asserted-by":"publisher","first-page":"10108","DOI":"10.1128\/JVI.79.16.10108-10125.2005","volume":"79","author":"M Li","year":"2005","unstructured":"Li, M. et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108\u201310125 (2005).","journal-title":"J. Virol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58371-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58371-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58371-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T05:54:31Z","timestamp":1743659671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58371-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":103,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["58371"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-58371-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"22 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.H.P. serves on the scientific advisory board of Allogene Tx and is an advisor to Versant Ventures. M.H.P. has equity in CRISPR Tx and has equity and is a founder of Kamau Therapeutics. M.H.P., W.N.F., and S.E.L. are inventors on a provisional patent application submitted by The Board of Trustees of the Leland Stanford Junior University to the United States Patent and Trademark Office pertaining to the genetic engineering of cells for section of therapeutic antibodies (application number 63\/561,249). The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3103"}}